Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rocconi, Rodney P
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer	Active, not recruiting	2	53	US	Abemaciclib, Letrozole	Gynecologic Oncology Group, Eli Lilly and Company	Endometrial Cancer	12/24	12/25
NCT05051722: Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer	Recruiting	2	2640	US	Tampon Collection, Vaginal Fluid, Blood Collection	Mayo Clinic	Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer	12/25	06/26
NCT01198171: Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer	Completed	N/A	243	US	Laboratory Biomarker Analysis, Study of Socioeconomic and Demographic Variables	Gynecologic Oncology Group, National Cancer Institute (NCI)	Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer	02/17	02/17
Broemmelsiek, Joanie
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer	Active, not recruiting	2	53	US	Abemaciclib, Letrozole	Gynecologic Oncology Group, Eli Lilly and Company	Endometrial Cancer	12/24	12/25
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	2	102	Europe, US, RoW	ZN-c3, azenosertib	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	04/25	10/25
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer Presentation of OVATION 2 data in advanced ovarian cancer Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer	Active, not recruiting	1/2	130	Canada, US	IMNN-001, Carboplatin, Paclitaxel	Imunon	Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	07/24	11/25